CONSULTING AGREEMENTConsulting Agreement • March 25th, 2024 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of May 16, 2023 (the “Effective Date”) by and between Mark Smith, with an address of [***] (“Consultant”), and Finch Therapeutics, Inc., a Delaware corporation with an address at 200 Inner Belt Road, Suite 400, Somerville, MA 02143 (“Finch”). Finch desires to obtain from Consultant various services, and Consultant desires to provide the services to Finch, all as provided in this Agreement. Each of Consultant and Finch may be referred to herein individually as a “Party,” or collectively as the “Parties”.
December 7, 2022 Marc Blaustein mblaustein@finchtherapeutics.com Dear Marc,Employment Agreement • March 25th, 2024 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances)
The purpose of this letter is to amend the Employment Agreement by and between Finch Therapeutics Group, Inc. (the “Company”) and you dated as of September 8, 2021 (the “Employment Agreement”), effective as of April 30, 2022 (the “Effective Date”). Capitalized terms used but not defined in this letter will have the meanings set forth in the Employment Agreement.
RETENTION BONUS AGREEMENTRetention Bonus Agreement • March 25th, 2024 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS RETENTION BONUS AGREEMENT (this “Agreement”), is made and entered into by and between Finch Therapeutics Group, Inc., a Delaware corporation (together with all subsidiaries and affiliates hereinafter referred to as the “Company”), and Marc Blaustein (the “Executive”) effective as of December 7, 2022.
